Quadrant Private Wealth Management, LLC Lineage Cell Therapeutics, Inc. Transaction History
Quadrant Private Wealth Management, LLC
- $429 Million
- Q2 2024
A detailed history of Quadrant Private Wealth Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Quadrant Private Wealth Management, LLC holds 10,000 shares of LCTX stock, worth $9,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 15,000
33.33%
Holding current value
$9,200
Previous $22,000
54.55%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.3MCall Options Held
31.3KPut Options Held
400-
Broadwood Capital Inc New York, NY41.7MShares$38.3 Million3.19% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$8.79 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.47MShares$7.8 Million0.0% of portfolio
-
Defender Capital, Llc.4.97MShares$4.58 Million1.77% of portfolio
-
Logos Global Management LP San Francisco, CA4.7MShares$4.32 Million0.44% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $156M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...